Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 278 M
EBIT 2016 -92,5 M
Net income 2016 -107 M
Debt 2016 47,8 M
Yield 2016 -
Sales 2017 321 M
EBIT 2017 -99,9 M
Net income 2017 -138 M
Debt 2017 77,8 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 16,1x
EV / Sales2017 14,1x
Capitalization 4 440 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates through two segments: Drug Discovery & Development Operations and Akcea.The Drug Discovery & Development Operations segment provides drugs to treat a variety of health conditions,... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
09/26 BIOGEN : Completes Rolling Submission of New Drug Application to FDA for Nusiner..
09/23 IONIS PHARMACEUTICALS INC : Other Events (form 8-K)
09/23 INTERLEUKIN GENETICS : Cites Role in Key Antisense Drug Trial Published in The L..
09/22 IONIS PHARMACEUTICALS : Akcea Announces Publication in The Lancet of Clinical Re..
09/20 INTERCEPT PHARMACEUTICALS : Biotechnology Stocks Seeing Notable Strength In Afte..
09/17 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals to Present at Upcoming Investor Con..
09/15 ISIS PHARMACEUTICALS : Akcea Therapeutics Announces Presentations of New Data Un..
09/01 IONIS PHARMACEUTICALS' : CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award..
08/31 IONIS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
08/22 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives ..
More news
Sector news : Biotechnology & Medical Research - NEC
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 40,2 $
Spread / Average Target 9,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Senior Vice President-Antisense Research
Joseph H. Wender Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%4 218
INCYTE CORPORATION-17.87%16 687
CELLTRION, INC.--.--%11 639
LONZA GROUP AG11.83%9 948
QUINTILES TRANSNATIONA..16.08%9 402
SEATTLE GENETICS, INC.26.05%7 828
More Results